FDA approves Perjeta for type of late-stage breast cancer
16:04 EDT 8 Jun 2012 | FDA
The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.
Original Article: FDA approves Perjeta for type of late-stage breast cancer
More From BioPortfolio on "FDA approves Perjeta for type of late-stage breast cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
